- Home
- ALLO vs AUTL Comparison
ALLO vs AUTL Comparison
Compare ALLO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- AUTL
- Stock Information
- Founded
- ALLO 2017
- AUTL 2014
- Country
- ALLO United States
- AUTL United Kingdom
- Employees
- ALLO N/A
- AUTL N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLO Health Care
- AUTL Health Care
- Exchange
- ALLO Nasdaq
- AUTL Nasdaq
- Market Cap
- ALLO 371.8M
- AUTL 359.3M
- IPO Year
- ALLO 2018
- AUTL 2018
- Fundamental
- Price
- ALLO $1.11
- AUTL $1.47
- Analyst Decision
- ALLO Strong Buy
- AUTL Strong Buy
- Analyst Count
- ALLO 10
- AUTL 5
- Target Price
- ALLO $8.90
- AUTL $9.32
- AVG Volume (30 Days)
- ALLO 4.1M
- AUTL 2.5M
- Earning Date
- ALLO 05-13-2025
- AUTL 05-08-2025
- Dividend Yield
- ALLO N/A
- AUTL N/A
- EPS Growth
- ALLO N/A
- AUTL N/A
- EPS
- ALLO N/A
- AUTL N/A
- Revenue
- ALLO N/A
- AUTL $9,011,000.00
- Revenue This Year
- ALLO N/A
- AUTL $271.57
- Revenue Next Year
- ALLO $9.07
- AUTL $217.37
- P/E Ratio
- ALLO N/A
- AUTL N/A
- Revenue Growth
- ALLO N/A
- AUTL N/A
- 52 Week Low
- ALLO $0.86
- AUTL $1.11
- 52 Week High
- ALLO $3.78
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- ALLO 38.30
- AUTL 54.12
- Support Level
- ALLO $1.07
- AUTL $1.19
- Resistance Level
- ALLO $1.15
- AUTL $1.44
- Average True Range (ATR)
- ALLO 0.14
- AUTL 0.12
- MACD
- ALLO -0.01
- AUTL 0.03
- Stochastic Oscillator
- ALLO 27.17
- AUTL 72.86
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.